Tag Archives: pharmaceutical

Data protection timing disputes for biologics pharmaceutical products and TPP

Posted on August 30, 2015 by aviyer2010

An article in the New York Times (July 30, 2015) titled “Patent Protection for Drugs puts Pressure on US in Trade Talks” (http://www.nytimes.com/2015/07/31/business/international/pacific-trade-deal-drugs-patent-protection.html?_r=0) describes a conflict between Trans-Pacific Partnership (TPP)  countries regarding the duration that data collected during development of … Continue reading →

Posted in Uncategorized | Tagged , , , , , , | Leave a comment

Software to track detailed flows from prescriptions to drug usage at the patient level

Posted on May 17, 2013 by aviyer2010

An article in the New York Times (May 16,2013) describes software that uses insurance records, claims etc to track individual drug prescriptions from doctors to patients to pharmacies, including refills, albeit without patient identifiers. But the data does include details … Continue reading →

Posted in Operations Management, Service Operations, Supply Chain Issues | Tagged , , , , , , , , , | Leave a comment

The 340B discount drug program and supply chain leakage

Posted on February 13, 2013 by aviyer2010

An article in the New York Times (February 12, 2013) describes problems with the 340B drug program that requires pharmaceutical companies to provide 20 to 50 % discount to hospitals treating low income and uninsured patients and accounts for about … Continue reading →

Posted in Global Contexts, Operations Management, Supply Chain Issues | Tagged , , , , , , , , | Leave a comment

Manufacturer’s efforts to prevent use of their drugs for lethal injections

Posted on February 10, 2013 by aviyer2010

An article in Bloombergbusinessweek (February 11,2013) describes efforts by European manufacturers to prevent use of their drugs for lethal injections in US prisons (to enforce the death penalty). Because capital punishment is illegal across Europe, European governments, such as Italy, … Continue reading →

Posted in Global Contexts, Operations Management, Supply Chain Issues | Tagged , , , , , , , , | Leave a comment

Using UPS to outsource drug delivery

Posted on September 2, 2012 by aviyer2010

An article in the Wall Street Journal (June 28,2012) describes pharmacists at UPS’s hub in Louisville filling prescriptions for insulin or other drugs for quick delivery to customers. The same supply chain allowed Walgreen to ship vaccines to Laos, with … Continue reading →

Posted in Ecommerce, Operations Management, Service Operations, Supply Chain Issues | Tagged , , , , , , , | Leave a comment

“Pay for response” model for drug payment and consequences

Posted on March 18, 2012 by aviyer2010

An Op-Ed by Sam Waksal in the New York Times (March 7,2012) suggests a pay for response model for drug payments, where the measurable impact of drugs would trigger payments. The author claims that such payment schemes would incent drug … Continue reading →

Posted in Operations Management, Service Operations, Supply Chain Issues | Tagged , , , , , , | 1 Comment

Making the case for “cost effectiveness” of new drugs

Posted on August 1, 2011 by aviyer2010

A story in the Wall Street Journal (August 1, 2011) describes the challenges in launching new drugs, given the “cost effectiveness” concern by health authorities. This means that new drugs have to be effective in treatment, but also deliver sufficient … Continue reading →

Posted in Operations Management, Service Operations, Supply Chain Issues | Tagged , , , , , | Leave a comment

FDA and large vs small scale drug manufacturing oversight

Posted on April 6, 2011 by aviyer2010

A New York Times article (April 4, 2011) describes the impact of decisions by the FDA not to regulate “compounding pharmacies” that make versions of drugs not commonly available (for example liquid forms of tablet medications).  The expectation is that … Continue reading →

Posted in Operations Management, Service Operations, Supply Chain Issues | Tagged , , , , | Leave a comment